Serum concentrations of para-aminosalicylic acid (PAS) produced by various forms of PAS.
نویسندگان
چکیده
Para-aminosalicylic acid (PAS) is now generally accepted as an effective antibacterial agent in the treatment of certain forms of tuberculosis when administered alone or in combination with one of the streptomycins. However, there remains a great deal of uncertainty as to the best method of administering the drug. Both the free acid and the sodium salt of PAS have been given in various dosage forms in an effort to diminish the symptoms of gastro-intestinal irritation which the drug produces. We have given the free acid as compressed uncoated tablets, entenic-coated tablets, entenic-coated granules, capsules, and as powder mixed with food or suspended in a liquid such as milk. The sodium salt has been given as a solution in water mixed with various fruit juices. Although an occasional patient preferred one of the forms of the free acid, most patients have been able to take larger daily doses of PAS as a solution of the sodium salt. This is In agreement with the reports of most clinical investigators. However, it is obvious that the total daily dose is of less importance than the concentration of PAS that is present in the blood serum after administration of each of these forms of the drug. In 1949 Lehmann’ advised against the use of the sodium salt of PAS stating, “We have generally used the PAS acid in the granules and not the sodium salt. The reason for not using the sodium salt is that it is very soluble in water, rapidly absorbed in the intestinal canal, and rapidly excreted by the kidneys. The blood level will therefore not be as high as one might except from the relatively large dose. The PAS acid is only soluble in 0.4 per cent in water and is not absorbed in the intestinal canal before neutralization by the intestinal juice.” More recently he2 has written, “Whether PAS should be used routinely as an acid enteric coated
منابع مشابه
Comparative study of concentrations in the blood of para-aminosalicylic acid in tuberculous patients.
In the Hospital Obrero of Lima we studied patients to determine concentration of PAS in blood plasma with the administration of its different forms. Sodium PAS was administered to nine patients, pure buffered PAS to 12, and PAS-K to six. The pure PAS used was buffered parasal with aluminum glycinate and calcium carbonate (Parlam-Panray); Sodium PAS was the usual and PAS-K was also of Parlam Lab...
متن کاملBrain regional pharmacokinetics of p-aminosalicylic acid and its N-acetylated metabolite: effectiveness in chelating brain manganese.
para-aminosalicylic acid (PAS; 4-amino-2-hydroxybenzoic acid), an antituberculosis drug in use since the 1950s, has recently been suggested to be an effective agent for treatment of manganese-induced parkinsonian disorders. However, the neuropharmacokinetics of PAS and its metabolite N-acetyl-para-aminosalicylic acid (AcPAS; N-acetyl-4-amino-2-hydroxybenzoic acid) are unknown. This study was de...
متن کاملPara-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis.
Folate biosynthesis is an established anti-infective target, and the antifolate para-aminosalicylic acid (PAS) was one of the first anti-infectives introduced into clinical practice on the basis of target-based drug discovery. Fifty years later, PAS continues to be used to treat tuberculosis. PAS is assumed to inhibit dihydropteroate synthase (DHPS) in Mycobacterium tuberculosis by mimicking th...
متن کاملChelation therapy of manganese intoxication with para-aminosalicylic acid (PAS) in Sprague-Dawley rats.
Para-aminosalicylic acid (PAS), an FDA-approved anti-tuberculosis drug, has been used successfully in the treatment of severe manganese (Mn)-induced Parkinsonism in humans [Jiang Y-M, Mo X-A, Du FQ, Fu X, Zhu X-Y, Gao H-Y, et al. Effective treatment of manganese-induced occupational Parkinsonism with p-aminosalicylic acid: a case of 17-year follow-up study. J Occup Environ Med 2006;48:644-9]. T...
متن کاملThe specific resistance of tubercle bacilli to para-aminosalicylic acid and sulfonamides.
The observation by Youmans et al. (1947) that para-aminobenzoic acid (PABA) antagonizes the action of para-aminosalicylic acid (PAS) has been confirmed repeatedly. Since the role of PABA has come to assume such a central position in explaining the mechanism and site of action of the sulfonamides, the question now arises, Do PAS and the sulfonamides inhibit the same metabolic process? The develo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Diseases of the chest
دوره 19 2 شماره
صفحات -
تاریخ انتشار 1951